ATE441663T1 - Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten - Google Patents
Verfahren und zusammensetzungen für amyloidosis- verbundene krankheitenInfo
- Publication number
- ATE441663T1 ATE441663T1 AT01970656T AT01970656T ATE441663T1 AT E441663 T1 ATE441663 T1 AT E441663T1 AT 01970656 T AT01970656 T AT 01970656T AT 01970656 T AT01970656 T AT 01970656T AT E441663 T1 ATE441663 T1 AT E441663T1
- Authority
- AT
- Austria
- Prior art keywords
- amyloidosis
- compositions
- present
- methods
- related diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Rehabilitation Therapy (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23039100P | 2000-09-06 | 2000-09-06 | |
US25503300P | 2000-12-12 | 2000-12-12 | |
PCT/US2001/027632 WO2002021141A2 (en) | 2000-09-06 | 2001-09-06 | Methods and compositions for diseases associated with amyloidosis |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE441663T1 true ATE441663T1 (de) | 2009-09-15 |
Family
ID=26924184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01970656T ATE441663T1 (de) | 2000-09-06 | 2001-09-06 | Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten |
Country Status (13)
Country | Link |
---|---|
US (4) | US7067133B2 (de) |
EP (3) | EP2067863A3 (de) |
JP (3) | JP5153986B2 (de) |
AT (1) | ATE441663T1 (de) |
AU (2) | AU2001290638C1 (de) |
CA (1) | CA2421374C (de) |
CY (1) | CY1110533T1 (de) |
DE (1) | DE60139788D1 (de) |
DK (1) | DK1317479T3 (de) |
ES (1) | ES2330082T3 (de) |
PT (1) | PT1317479E (de) |
SI (1) | SI1317479T1 (de) |
WO (1) | WO2002021141A2 (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
PL218883B1 (pl) | 2000-02-24 | 2015-02-27 | Lilly Co Eli | Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
PT1944040E (pt) | 2001-08-17 | 2012-10-31 | Univ Washington | Método de avaliação para a doença de alzheimer |
WO2003039467A2 (en) * | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid. |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
EP1596809B1 (de) | 2003-02-10 | 2010-05-26 | Applied Molecular Evolution, Inc. | Abeta-bindende moleküle |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US7807171B2 (en) | 2003-07-25 | 2010-10-05 | Ac Immune Sa | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
US20060069010A1 (en) * | 2003-10-17 | 2006-03-30 | Senicure Llc | Detoxification depot for Alzheimer's disease |
JP2008505116A (ja) * | 2004-07-02 | 2008-02-21 | ユニバーシティー オブ ピッツバーグ | アミロイド沈着を伴う疾患の前駆形態の診断方法 |
KR20070085224A (ko) * | 2004-08-03 | 2007-08-27 | 바이오렉시스 파마슈티칼 코포레이션 | Glp-1을 포함하는 트랜스페린 융합 단백질을 사용하는혼합 요법 |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
PE20061401A1 (es) * | 2004-12-15 | 2006-12-23 | Neuralab Ltd | ANTICUERPOS Aß PARA MEJORAR LA COGNICION |
DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
WO2007062852A2 (en) | 2005-11-30 | 2007-06-07 | Abbott Laboratories | ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES |
KR101505201B1 (ko) | 2005-12-12 | 2015-03-24 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
NZ568384A (en) * | 2005-12-12 | 2011-09-30 | Ac Immune Sa | Therapeutic vaccine comprising Abeta peptide |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
AR062065A1 (es) * | 2006-07-14 | 2008-10-15 | Ac Immune Sa | Anticuerpo humanizado |
AU2007278994B2 (en) | 2006-07-24 | 2013-08-15 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
JP5959795B2 (ja) * | 2006-08-18 | 2016-08-02 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | 血液脳関門送達のための物質 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US8066999B2 (en) | 2007-01-18 | 2011-11-29 | Eli Lilly And Company | PEGylated Aβ fab |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
NZ581834A (en) * | 2007-06-12 | 2012-06-29 | Ac Immune Sa | Humanized antibodies to amyloid beta |
BRPI0818643A2 (pt) * | 2007-10-05 | 2017-05-23 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga de placa na camada celular de gânglio retinal de um paciente, para reduzir a quantidade de placas na camada celular de gânglio retinal de um paciente, para diminuir a quantidade total de amilóide-beta solúvel na camada celular de gânglio retinal de um paciente, para evitar, tratar ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para diagnosticar uma predisposição a uma doença ocular associada com anormalidades patológicas/mudanças nos tecidos dos sistema visual, para monitorar doenças ocular mínima residual associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer a responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um paciente |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2011119608A1 (en) * | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
EP2598882B1 (de) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose |
US9289488B2 (en) | 2010-08-12 | 2016-03-22 | Ac Immune Sa | Vaccine engineering |
CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
US9687447B2 (en) | 2010-10-26 | 2017-06-27 | Ac Immune S.A. | Method for preparing liposome-based constructs |
TWI689314B (zh) | 2010-11-30 | 2020-04-01 | 建南德克公司 | 低親和力血腦障壁受體抗體及其用途 |
JP2012233002A (ja) * | 2012-08-03 | 2012-11-29 | Janssen Alzheimer Immunotherapy | 認知の改善における使用のためのアミロイドβ抗体 |
US9588129B2 (en) * | 2013-03-15 | 2017-03-07 | Amira Medical Technologies Inc. | Methods for analyzing blood to detect diseases associated with abnormal protein aggregation |
WO2015017280A1 (en) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
CA2938152A1 (en) * | 2014-02-10 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antibodies that bind to human tau and assay for quantifying human tau using the antibodies |
EP3316225B1 (de) | 2016-11-01 | 2021-03-10 | Swiss Timing Ltd. | Modul mit transponder zur bestimmung einer durchlaufzeit in einem messsystem |
EP3681909A1 (de) * | 2017-09-14 | 2020-07-22 | Denali Therapeutics Inc. | Anti-trem2-antikörper und verfahren zur verwendung davon |
JP2021510162A (ja) * | 2018-01-10 | 2021-04-15 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | トランスフェリン受容体結合ポリペプチド及びその使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5583198A (en) * | 1989-12-22 | 1996-12-10 | Commonwealth Scientific And Industrial Research Organization | Amino acids, peptides or derivatives thereof coupled to fats |
US5580563A (en) * | 1992-05-01 | 1996-12-03 | Tam; James P. | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof |
GB9215780D0 (en) * | 1992-07-24 | 1992-09-09 | Univ London Pharmacy | Peptide compounds |
AU8269898A (en) * | 1997-06-27 | 1999-01-19 | Regents Of The University Of California, The | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6372720B1 (en) * | 1998-02-05 | 2002-04-16 | Kenneth J. Longmuir | Liposome fusion and delivery vehicle |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
-
2001
- 2001-09-06 EP EP08014103.9A patent/EP2067863A3/de not_active Withdrawn
- 2001-09-06 WO PCT/US2001/027632 patent/WO2002021141A2/en active Application Filing
- 2001-09-06 AU AU2001290638A patent/AU2001290638C1/en not_active Ceased
- 2001-09-06 SI SI200130939T patent/SI1317479T1/sl unknown
- 2001-09-06 ES ES01970656T patent/ES2330082T3/es not_active Expired - Lifetime
- 2001-09-06 JP JP2002524709A patent/JP5153986B2/ja not_active Expired - Fee Related
- 2001-09-06 US US09/948,049 patent/US7067133B2/en not_active Expired - Lifetime
- 2001-09-06 PT PT01970656T patent/PT1317479E/pt unknown
- 2001-09-06 EP EP10184152.6A patent/EP2305822A3/de not_active Withdrawn
- 2001-09-06 EP EP01970656A patent/EP1317479B1/de not_active Expired - Lifetime
- 2001-09-06 DE DE60139788T patent/DE60139788D1/de not_active Expired - Lifetime
- 2001-09-06 AU AU9063801A patent/AU9063801A/xx active Pending
- 2001-09-06 AT AT01970656T patent/ATE441663T1/de active
- 2001-09-06 CA CA2421374A patent/CA2421374C/en not_active Expired - Fee Related
- 2001-09-06 DK DK01970656T patent/DK1317479T3/da active
-
2005
- 2005-09-16 US US11/229,264 patent/US20060073155A1/en not_active Abandoned
-
2009
- 2009-04-15 US US12/424,034 patent/US20090202627A1/en not_active Abandoned
- 2009-11-11 CY CY20091101176T patent/CY1110533T1/el unknown
-
2011
- 2011-12-21 JP JP2011280015A patent/JP2012072182A/ja active Pending
-
2013
- 2013-10-16 JP JP2013215789A patent/JP2014030427A/ja active Pending
-
2017
- 2017-03-22 US US15/466,522 patent/US20170320938A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU9063801A (en) | 2002-03-22 |
SI1317479T1 (sl) | 2010-01-29 |
WO2002021141A3 (en) | 2003-01-16 |
DE60139788D1 (de) | 2009-10-15 |
AU2001290638B2 (en) | 2007-09-06 |
PT1317479E (pt) | 2009-10-29 |
US20020156036A1 (en) | 2002-10-24 |
EP2305822A2 (de) | 2011-04-06 |
JP5153986B2 (ja) | 2013-02-27 |
DK1317479T3 (da) | 2009-11-23 |
US20170320938A1 (en) | 2017-11-09 |
AU2001290638C1 (en) | 2009-04-30 |
CA2421374A1 (en) | 2002-03-14 |
JP2014030427A (ja) | 2014-02-20 |
EP1317479B1 (de) | 2009-09-02 |
CY1110533T1 (el) | 2015-04-29 |
JP2005504714A (ja) | 2005-02-17 |
CA2421374C (en) | 2017-03-07 |
JP2012072182A (ja) | 2012-04-12 |
EP2305822A3 (de) | 2013-11-06 |
EP1317479A2 (de) | 2003-06-11 |
EP2067863A3 (de) | 2013-11-06 |
US20060073155A1 (en) | 2006-04-06 |
US7067133B2 (en) | 2006-06-27 |
EP2067863A2 (de) | 2009-06-10 |
ES2330082T3 (es) | 2009-12-04 |
US20090202627A1 (en) | 2009-08-13 |
WO2002021141A2 (en) | 2002-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60139788D1 (de) | Verfahren und zusammensetzungen für amyloidosis-verbundene krankheiten | |
CY2020003I2 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
ATE490262T1 (de) | Abschwächung der immunogenizität von fusionsproteinen | |
IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
CY1107146T1 (el) | Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad) | |
DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
ATE479442T1 (de) | Beta-amyloidpeptid erkennende humanisierte antikörper | |
MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
ATE485371T1 (de) | Varianten des menschlichen koagulationsfaktors vii | |
DE60045721D1 (de) | Streptococcus pneumoniae Proteine und Impfstoffe | |
EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
DE60143065D1 (de) | Bildgebende Verfahren, Diagnose und Behandlung von Krankheiten | |
WO2002059346A3 (en) | Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents | |
DE60140972D1 (de) | Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen | |
DK0786004T3 (da) | Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase | |
EA200100700A1 (ru) | Гены и белки и их применение | |
ATE348161T1 (de) | Fctrx genannte proteine und dafür kodierende nuklein säure | |
EA200100701A1 (ru) | Белки наружной поверхности, их гены и их применение | |
ATE397753T1 (de) | Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung | |
DE60215594D1 (de) | Auswertung von Agenzien zur Behandlung von Schizophrenie | |
DE60223674D1 (de) | Vektoren zur gesteigerten expression von vegf zur behandlung von krankheiten | |
ATE421586T1 (de) | Moraxella (branhamella) catarrhalis antigene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1317479 Country of ref document: EP |